Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(CSE: ONCO )

2.580 +0.080 (+3.20%)
Official Closing Price Updated: 3:59 PM EST, Feb 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ONCO

Onco-Innovations Provides Information Regarding Inka Health's USPTO Provisional Patent Application for AI-Powered Precision Medicine Platform, SynoGraph
Via ACCESS Newswire
Onco-Innovations Announces U.S. Listing on the OTCQB Market
Via ACCESS Newswire
Onco-Innovations' Nanoparticle Formulation PNKP Technology Combined with Radiation Therapy, and as a Standalone Treatment, Shown in Studies to Slow Colorectal Cancer Tumour Growth
Via ACCESS Newswire
Onco-Innovations' Licensed PNKP Inhibitor Technology Shown to Increase Sensitivity of Cancer Cells to Radiation in Animal Study
Via ACCESS Newswire
Onco-Innovations' Private Placement Fully Subscribed
Via ACCESS Newswire
Onco-Innovations Announces Expression of Interest Between Inka Health and Global Data Leader, Quantify Research
Via ACCESS Newswire
Onco-Innovations Completes Acquisition of Inka Health to Accelerate AI-Driven Cancer Research and Drug Development
Via ACCESS Newswire
Onco-Innovations' Licensed Technology Shows Promise in Enhancing Chemotherapy Effectiveness by Overcoming Cancer Cell Resistance and Inhibiting Cancer Cell Repair
Via ACCESS Newswire
Onco-Innovations Unaware of Any Material Change
Via ACCESS Newswire
Onco-Innovations Enters into LOI with Inka Health to Implement AI Technology Toward Cancer Detection and Drug Development
Via ACCESS Newswire
Onco-Innovations' Licensed Technology Shown in Study to Successfully Prevent Regeneration of Cancer Cells
Via ACCESS Newswire
Onco-Innovations' Technology Shown in Study to Successfully Inactivate DNA Repair in Cancer, Potentially Boosting Radiation Therapy Effectiveness
Via ACCESSWIRE
Onco-Innovations Provides Information Regarding Exclusive License for Patented Drug with Potential to Enhance Cancer Treatment Options
Via ACCESSWIRE
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.